ResearcherItalian Institute of TechnologyActive in the last 2 years
Fabrizio Schipani
Matched on ORCID iD 0000-0002-4386-1201; OpenAlex author ID A5001425843. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibiti… Co-author DOI 10.1016/j.ejmech.2023.116114↗
- RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer Co-author DOI 10.1101/2021.02.03.429564↗
- Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Ol… Co-author DOI 10.1021/acs.jmedchem.9b01526↗
- Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. First author DOI 10.1016/j.ejmech.2019.01.008↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marinella Roberti · 4 shared papers, 2019–2024 · strength 0.46
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer DOI 10.1101/2021.02.03.429564↗
- Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
- Stefania Girotto · 4 shared papers, 2019–2024 · strength 0.46
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer DOI 10.1101/2021.02.03.429564↗
- Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
- Andrea Cavalli · 4 shared papers, 2019–2024 · strength 0.46
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer DOI 10.1101/2021.02.03.429564↗
- Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
- Greta Bagnolini · 3 shared papers, 2019–2024 · strength 0.34
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
- Paper Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. DOI 10.1016/j.ejmech.2019.01.008↗
- Naomi Walsh · 1 shared paper, 2024 · strength 0.18
- Samuel Harry Myers · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.